Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698138 | 1.00 | NOD1 (0.48) | NOD1ACE2SLC6A5HDAC2CA2 | |
| SCHEMBL4008880 | 0.90 | NOD1 (0.43) | NOD1ACE2SLC6A5HDAC2GNPAT | |
| SCHEMBL5698087 | 0.90 | NOD1 (0.43) | NOD1ACE2SLC6A5HDAC2GNPAT | |
| SCHEMBL7176520 | 0.89 | NOD1 (0.58) | NOD1SLC6A5HDAC2CA2GNPAT | |
| SCHEMBL7176522 | 0.89 | NOD1 (0.58) | NOD1SLC6A5HDAC2CA2GNPAT | |
| SCHEMBL4007723 | 0.85 | NOD1 (0.41) | NOD1SLC6A5GNPAT | |
| SCHEMBL7175773 | 0.81 | NOD1 (0.49) | NOD1SLC6A5HDAC2GNPAT | |
| SCHEMBL7175771 | 0.81 | NOD1 (0.49) | NOD1SLC6A5HDAC2GNPAT | |
| SCHEMBL19586694 | 0.80 | FOLH1 (0.42) | NOD1SLC6A5GNPAT | |
| SCHEMBL19586695 | 0.80 | FOLH1 (0.42) | NOD1SLC6A5GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | claimed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | claimed |
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | NOD1 3810/4885ACE2 660/4885SLC6A5 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.